Switch theme
Sign up to access all valuation multiples
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
1990
56K+
LTM Revenue $10.3B
LTM EBITDA $2.0B
$25.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Quest Diagnostics has a last 12-month revenue (LTM) of $10.3B and a last 12-month EBITDA of $2.0B.
In the most recent fiscal year, Quest Diagnostics achieved revenue of $9.9B and an EBITDA of $1.9B.
Quest Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Quest Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3B | XXX | $9.9B | XXX | XXX | XXX |
| Gross Profit | $3.4B | XXX | $3.2B | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $2.0B | XXX | $1.9B | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $1.6B | XXX | $1.3B | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $1.1B | XXX | $871M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Quest Diagnostics's stock price is $173.
Quest Diagnostics has current market cap of $19.4B, and EV of $25.7B.
See Quest Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.7B | $19.4B | XXX | XXX | XXX | XXX | $9.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Quest Diagnostics has market cap of $19.4B and EV of $25.7B.
Quest Diagnostics's trades at 2.6x EV/Revenue multiple, and 13.6x EV/EBITDA.
Equity research analysts estimate Quest Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Quest Diagnostics has a P/E ratio of 18.4x.
See valuation multiples for Quest Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.4B | XXX | $19.4B | XXX | XXX | XXX |
| EV (current) | $25.7B | XXX | $25.7B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 13.6x | XXX | XXX | XXX |
| EV/EBIT | 15.9x | XXX | 19.1x | XXX | XXX | XXX |
| EV/Gross Profit | 7.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.4x | XXX | 22.2x | XXX | XXX | XXX |
| EV/FCF | 26.3x | XXX | 28.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQuest Diagnostics's last 12 month revenue growth is 7%
Quest Diagnostics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $34K for the same period.
Quest Diagnostics's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Quest Diagnostics's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Quest Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $34K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Quest Diagnostics acquired XXX companies to date.
Last acquisition by Quest Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Quest Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Quest Diagnostics founded? | Quest Diagnostics was founded in 1990. |
| Where is Quest Diagnostics headquartered? | Quest Diagnostics is headquartered in United States of America. |
| How many employees does Quest Diagnostics have? | As of today, Quest Diagnostics has 56K+ employees. |
| Who is the CEO of Quest Diagnostics? | Quest Diagnostics's CEO is Mr. James E. Davis. |
| Is Quest Diagnostics publicy listed? | Yes, Quest Diagnostics is a public company listed on NYS. |
| What is the stock symbol of Quest Diagnostics? | Quest Diagnostics trades under DGX ticker. |
| When did Quest Diagnostics go public? | Quest Diagnostics went public in 1996. |
| Who are competitors of Quest Diagnostics? | Similar companies to Quest Diagnostics include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Quest Diagnostics? | Quest Diagnostics's current market cap is $19.4B |
| What is the current revenue of Quest Diagnostics? | Quest Diagnostics's last 12 months revenue is $10.3B. |
| What is the current revenue growth of Quest Diagnostics? | Quest Diagnostics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Quest Diagnostics? | Current revenue multiple of Quest Diagnostics is 2.5x. |
| Is Quest Diagnostics profitable? | Yes, Quest Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Quest Diagnostics? | Quest Diagnostics's last 12 months EBITDA is $2.0B. |
| What is Quest Diagnostics's EBITDA margin? | Quest Diagnostics's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Quest Diagnostics? | Current EBITDA multiple of Quest Diagnostics is 12.7x. |
| What is the current FCF of Quest Diagnostics? | Quest Diagnostics's last 12 months FCF is $979M. |
| What is Quest Diagnostics's FCF margin? | Quest Diagnostics's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Quest Diagnostics? | Current FCF multiple of Quest Diagnostics is 26.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
